GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Valuation Rank

Neurogene (Neurogene) Valuation Rank


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Neurogene Valuation Rank Related Terms

Thank you for viewing the detailed overview of Neurogene's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurogene (Neurogene) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.